Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas

Xinyuan Zhang, Shisan Bao, Donna Lai, Robert W Rapkins, Mark C Gillies, Xinyuan Zhang, Shisan Bao, Donna Lai, Robert W Rapkins, Mark C Gillies

Abstract

Objective: To elucidate the mechanism of the unique beneficial effect of intravitreal steroid therapy on diabetic macular edema, we investigated the effect of locally administered triamcinolone acetonide (TA) on the expression of vascular endothelial growth factor (VEGF)-A and its receptors in retinas of rats with streptozotocin (STZ)-induced diabetes. We then correlated the expression of these proteins with breakdown of the blood-retinal barrier (BRB).

Research design and methods: Thirty-two eyes of 16 diabetic and nondiabetic rats were divided into four groups. TA was injected into the vitreous of the right eye, and saline was injected into the left eye (control) 3.5 weeks after induction of diabetes. Retinas were harvested 48 h following treatment. mRNA and protein expression of VEGF-A, VEGF-A receptor 1 (fms-like tyrosine kinase [FLT]-1), and VEGF-A receptor 2 (fetal liver kinase [FLK]-1) were determined by real-time RT-PCR and immunohistochemistry. BRB permeability was quantitated by measuring extravasated endogenous albumin and retinal thickness.

Results: Diabetes-induced retinal thickness and albumin extravasation were significantly reduced in TA-treated diabetic retinas to a level similar to that in sham-treated nondiabetic eyes. A close correlation between albumin leakage and increased expression of both Vegf-a and Flk-1 was noted in the diabetic retinas. TA downregulated the expression of Vegf-a and Flk-1 but upregulated the expression of Flt-1. TA did not alter the expression of these genes in nondiabetic retinas.

Conclusions: Intravitreal injection of TA stabilizes the BRB in association with regulation of Vegf-a, Flk-1, and Flt-1 expression in retinas in the early stages of diabetes.

Figures

FIG. 1.
FIG. 1.
mRNA expression ratios for Vegf-a, Flk-1 and Flt-1. A: Sham-treated diabetic retina/sham-treated nondiabetic retina. B: IVTA-treated diabetic retina/sham-treated diabetic retina. C: IVTA-treated nondiabetic retina/sham-treated nondiabetic retina.
FIG. 2.
FIG. 2.
Quantification analysis of VEGF-A, FLK-1, and FLT-1 distribution in the retina from different treatment groups. Number of positive cells for VEGF-A (A), FLK-1 (B), and FLT-1 (C) per millimeter (means ± SEM, n = 8). ***P < 0.001.
FIG. 3.
FIG. 3.
Retinal thickness was measured on H&E-stained sections at the similar location. The micrograph shows representative samples from IVTA-treated nondiabetic retina (A), sham-treated nondiabetic retina (B), IVTA-treated diabetic retina (C), and sham-treated diabetic retina (D). The yellow bar in A demonstrates one measurement of retinal thickness. E: Table showing mean (± SEM) retinal thickness (*** P < 0.001). Original magnifications ×200. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium layer; OS, inner and outer photoreceptor segment; CH, choroidal layer. To view a high-quality digital representation of this image, go to http://dx.doi.org/db07-0982.
FIG. 4.
FIG. 4.
Immunohistochemical analysis of retinal albumin distribution. Albumin was detected (in red) within the vessels in sham-treated nondiabetic retinas (A). A similar pattern of albumin distribution was observed in IVTA-treated diabetic retina, but with slightly higher expression in extra vascular space (B). Diffuse extravascular albumin was observed in the inner nuclear, outer plexiform, and outer nuclear layers in sham-treated diabetic retina (C). Extravasated albumin (arrows in C) was marked green in panel A1, B1, and C1 (corresponding to panels A, B, and C) by IPP4.5. Intravascular albumin was excluded by the analysis (arrow heads in C1). D: Quantification of albumin distribution/leakage in the four treatment groups. Values were presented as IAU. Data are means ± SEM, n = 8; *** P < 0.001. Original magnifications ×400. To view a high-quality digital representation of this image, go to http://dx.doi.org/db07-0982.

References

    1. Kohner EM: Diabetic retinopathy and high blood pressure: defining the risk. Am J Hypertens 10:181S–183S, 1997
    1. Group ETDRSR: Effects of asprin treatment on diabetic retinopathy ETDRS report number 8. Opthalmology 98 (Suppl.):757–765, 1991
    1. Sander B, Larsen M, Moldow B, Lund-Andersen H: Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. Invest Ophthalmol Vis Sci 42:433–438, 2001
    1. Engler CB, Sander B, Larsen M, Koefoed P, Parving HH, Lund-Andersen H: Probenecid inhibition of the outward transport of fluorescein across the human blood-retina barrier. Acta Ophthalmol (Copenh) 72:663–667, 1994
    1. Vinores SA, McGehee R, Lee A, Gadegbeku C, Campochiaro PA: Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats. J Histochem Cytochem 38:1341–1352, 1990
    1. Xu Q, Qaum T, Adamis AP: Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42:789–794, 2001
    1. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408–2413, 2001
    1. Mathews MK, Merges C, McLeod DS, Lutty GA: Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 38:2729–2741, 1997
    1. Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, Poulaki V, Ma JJ, Redmond TM, Liu S, Adamis AP, D'Amato RJ: Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 158:1161–1172, 2001
    1. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 58:1278–1284, 1998
    1. Cébe-Suarez AZ-FaKB-H: The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63:601–615, 2006
    1. Cunningham ET, Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747–1757, 2005
    1. Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP: Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 114:1702–1712, 2007
    1. Jonas JB, Kreissig I, Sofker A, Degenring RF: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57–61, 2003
    1. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927, 2002
    1. Edelman JL, Lutz D, Castro MR: Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 80:249–258, 2005
    1. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N: Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46:1440–1444, 2005
    1. Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533–1538, 2006
    1. Murata TNK, Khalil A, Ishibashi T, Inomata H, Sueishi K: The relation between expression of vasucular endothelial growth factor and breakdown of blood-retinal barrier in diabetic rat retina. Lab Invest 74:819–825, 1996
    1. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y: In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 39:2190–2194, 1998
    1. Murata TIT, Inomata H: Immunohistochemical detection of blood-retinal barrier breakdown in steptozotocin-diabetic rats. Graefe's Archive for Clinical and Experimental Ophthalmology 231:175–177, 1993
    1. Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S, Barter PJ: Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25:2416–2421, 2005
    1. Francisco JS, Moraes HP, Dias EP: Evaluation of the Image-Pro Plus 4.5 software for automatic counting of labeled nuclei by PCNA immunohistochemistry. Pesqui Odontol Bras 18:100–104, 2004
    1. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, Kopf M: The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264:561–563, 1994
    1. Ojima T, Takagi H, Suzuma K, Oh H, Suzuma I, Ohashi H, Watanabe D, Suganami E, Murakami T, Kurimoto M, Honda Y, Yoshimura N: EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol 168:331–339, 2006
    1. Lafuente JV, Argandona EG, Mitre B: VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers. J Neural Transm 113:487–496, 2006
    1. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22:1–29, 2003
    1. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988–26995, 1994
    1. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276:3222–3230, 2001
    1. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT: Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81:154–162, 1997
    1. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G: Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47:401–406, 1998
    1. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533–1538, 2006
    1. Barnes PJ: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 94:557–572, 1998
    1. Felinski EA, Antonetti DA: Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 30:949–957, 2005
    1. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274:23463–23467, 1999
    1. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC, Jr.: Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 80:667–677, 2002
    1. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113:642, e641–644, 2006
    1. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583, 2007
    1. Gillies MC, Tien YW: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 356:747–750, 2007
    1. van Wijngaarden P, Coster DJ, Williams KA: Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293:1509–1513, 2005
    1. Wenzel A, Grimm C, Seeliger MW, Jaissle G, Hafezi F, Kretschmer R, Zrenner E, Reme CE: Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 42:1653–1659, 2001
    1. Vinores S: Assessment of blood-retinal barrier integrity. Histol Histopath 10:141–154, 1995
    1. Bahcekapili N, Uzum G, Gokkusu C, Kuru A, Ziylan YZ: The relationship between erythropoietin pretreatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats. Life Sci 80:1245–1251, 2007
    1. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ: Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111:1543–1550, 2005
    1. Lip PL, Chatterjee S, Caine GJ, Hope-Ross M, Gibson J, Blann AD, Lip GY: Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 88:1543–1546, 2004

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する